• Genetic Analysis won US patent 12,596,121 covering companion diagnostic method to predict IBS patient response to low-FODMAP diet or fecal microbiota transplant.
• Method uses gut microbiota profiling to separate likely responders from non-responders, aiming to guide treatment selection.
• Patent family claims priority from Oct. 14, 2016; protection runs to Nov. 21, 2040.
• Company cited IBS prevalence of 5%-10% globally, annual US cost burden of about USD 30 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genetic Analysis AS published the original content used to generate this news brief via Cision (Ref. ID: 202605070400BITN____UKPR__EN_20260507-BIT-9766-0) on May 07, 2026, and is solely responsible for the information contained therein.